Capricor Therapeutics Inc (CAPR) - Financial Analysis Review - GlobalData - Company Reports

Capricor Therapeutics Inc (CAPR) - Financial Analysis Review

Capricor Therapeutics Inc (CAPR) - Financial Analysis Review - GlobalData - Company Reports
Capricor Therapeutics Inc (CAPR) - Financial Analysis Review
Published Nov 22, 2016
39 pages — Published Nov 22, 2016
Price US$ 125.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Capricor Therapeutics Inc (Capricor) discovers, develops and commercializes therapeutics for various diseases. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced heart failure and duchenne muscular dystrophy associated cardiomyopathy. It offers CAP- 1002, a lead product for the treatment of cardiomyopathy; cendertide and exosome products. Capricor conducts research and development on its exosomes platform technology. The company offers development for the outpatient treatment of heart failure and potential other indications. It offers research programs on cell therapy, natriuretic peptides and exosome platforms.

GlobalData's Capricor Therapeutics Inc (CAPR) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Capricor Therapeutics Inc Key Recent Developments:

Aug 15,2016: Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update
Jun 16,2016: Clinical Trial to Repair Damaged Heart Muscle With Cardiac Stem Cells Currently Underway at Lenox Hill Hospital
May 12,2016: Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
Mar 17,2016: Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
Feb 23,2016: Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public compani

  
Source:
Document ID
GDPH485930FA
Country
Industry
Ticker
CAPR=US
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Section 1 - About the Company41
Capricor Therapeutics Inc - Key Facts51
Capricor Therapeutics Inc - Key Employees61
Capricor Therapeutics Inc - Major Products and Services71
Capricor Therapeutics Inc - Pharmaceutical Pipeline Products Data83
  Capricor Therapeutics Inc, Pipeline Products by Therapy Area81
  Capricor Therapeutics Inc, Pipeline Products by Development Phase92
Capricor Therapeutics Inc - History111
Capricor Therapeutics Inc - Locations And Subsidiaries121
  Head Office121
  Other Locations &Subsidiaries121
Section 2 Company Analysis131
Company Overview131
Capricor Therapeutics Inc - Key Competitors141
Section 3 Company Financial Ratios151
Financial Ratios - Capital Market Ratios151
Financial Ratios - Annual Ratios162
Performance Chart181
Financial Performance181
Financial Ratios - Interim Ratios191
Financial Ratios - Ratio Charts201
Section 4 Company s Lifesciences Financial Deals and Alliances212
  Capricor Therapeutics Inc, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016211
  Capricor Therapeutics Inc, Pharmaceuticals &Healthcare, Deals By Type, 2010 to YTD 2016221
Capricor Therapeutics Inc, Recent Deals Summary231
Section 5 Company s Recent Developments241
Aug 15, 2016: Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update241
Jun 16, 2016: Clinical Trial to Repair Damaged Heart Muscle With Cardiac Stem Cells Currently Underway at Lenox Hill Hospital251
May 12, 2016: Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results261
Mar 17, 2016: Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update271
Feb 23, 2016: Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer281
Nov 12, 2015: Capricor Therapeutics Reports Third Quarter 2015 Business &Financial Highlights292
Aug 13, 2015: Capricor Therapeutics Reports Second Quarter 2015 Business &Financial Highlights311
Aug 04, 2015: Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer321
Jun 17, 2015: Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies331
May 12, 2015: Capricor Therapeutics Reports First Quarter 2015 Financial &Business Highlights341
Section 6 Appendix355
  Methodology351
  Ratio Definitions354
  About GlobalData391
  Contact Us391
  Disclaimer391

Table Of Contents

GlobalData - Company Reports—GlobalData is an industry analysis specialist, providing business information products and services. These high quality company reports are created via a large research and analysis capability, drawing from extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
GlobalData - Company Reports. "Capricor Therapeutics Inc (CAPR) - Financial Analysis Review" Nov 22, 2016. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Capricor-Therapeutics-Inc-CAPR-Financial-Analysis-Review-2087-64318>
  
APA:
GlobalData - Company Reports. (2016). Capricor Therapeutics Inc (CAPR) - Financial Analysis Review Nov 22, 2016. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Capricor-Therapeutics-Inc-CAPR-Financial-Analysis-Review-2087-64318>
  
US$ 125.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Company Profiles from one place.